
ANIX Stock Forecast & Price Target
ANIX Analyst Ratings
Bulls say
Anixa Biosciences is well-positioned in the immuno-oncology space, with both its cancer prevention and treatment approaches showing promising results. The ongoing Phase 1 trials for its breast cancer vaccine and lira-cel therapies have shown positive signals, supporting continued clinical advancement and investor interest. Additionally, their unique mechanism of using chimeric endocrine receptor T cell (CER-T) technology and targeting the follicle stimulating hormone receptor (FSHR) sets them apart from conventional CAR-T therapies and may offer a more targeted and potentially less toxic approach.
Bears say
Anixa Biosciences is set to participate in the Water Tower Research Insights Conference on April 14, where they are expected to showcase positive Phase 1 data from their breast cancer vaccine and encouraging survival signals from their ovarian cancer CAR-T program. However, despite this early momentum, the company's legacy operations and limited patent licensing activities do not generate significant revenue. Additionally, with only one program currently in clinical trials, there may be limited diversity in their pipeline and success may be heavily dependent on the success of lira-cel.
This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
ANIX Analyst Forecast & Price Prediction
Start investing in ANIX
Order type
Buy in
Order amount
Est. shares
0 shares